<DOC>
	<DOCNO>NCT00868426</DOCNO>
	<brief_summary>The aim pilot study ass methodology , practical arrangement pulmonary absorption charcoal blockage future bioequivalence study . In addition , PK budesonide formoterol administration 2 different batch Symbicort TH compare .</brief_summary>
	<brief_title>Pharmacokinetic Pilot Study Budesonide/Formoterol Device-metered Dry Powder Inhaler</brief_title>
	<detailed_description />
	<mesh_term>Budesonide , Formoterol Fumarate Drug Combination</mesh_term>
	<mesh_term>Formoterol Fumarate</mesh_term>
	<mesh_term>Budesonide</mesh_term>
	<mesh_term>Charcoal</mesh_term>
	<criteria>Good general health ascertain detailed medical history , laboratory physical examination Finnish speaking male female , 1855 ( inclusive ) year age Normal weight define body mass index ( BMI ) &gt; 19 &lt; 30 kg/m2 Weight least 50 kg Regular intestinal transit Evidence clinically significant cardiovascular , renal , hepatic , haematological , gastrointestinal , pulmonary , metabolicendocrine , neurological psychiatric disease Any abnormal value laboratory , vital sign , 12lead electrocardiogram physical exam may opinion investigator interfere test result cause health risk subject he/she take part study Any condition require regular concomitant treatment ( include vitamin herbal product ) likely need concomitant treatment study Known hypersensitivity active substance ( ) excipients drug Pregnant lactating female Recent current ( suspect ) drug abuse positive result drug abuse test Recent current alcohol abuse ( regular drinking 21 unit per week male 16 unit per week female [ 1 unit = 4 cl spirit equivalent ] ) Current use nicotine containing product 5 cigarette ( equivalent ) /day and/or inability refrain use nicotine containing product study Use caffeine contain beverage 600 mg caffeine/day and/or inability refrain use caffeine contain beverage treatment period 24 h study treatment administration Blood donation loss significant amount blood within 90 day prior first study treatment administration Administration another investigational drug within 90 day prior first study treatment administration Unsuitable vein repeat venipuncture cannulation Inability learn correct inhalation technique Inability participate treatment period</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>July 2009</verification_date>
	<keyword>Healthy volunteer study</keyword>
</DOC>